**Induction of CD4⁺ and CD8⁺ T-Cell Responses to the Human Stromal Antigen, Fibroblast Activation Protein: Implication for Cancer Immunotherapy**

Martin Fassnacht, Jaewoo Lee, Caterina Milazzo, David Boczkowski, Zhen Su, Smita Nair, and Eli Gilboa

**Abstract**

**Purpose:** The propensity of tumor cells to escape immune elimination could limit, if not defeat, the long-term benefits of effective immunotherapeutic protocols. Immunologic targeting of tumor stroma could significantly reduce the ability of tumors to evade immune elimination. Murine studies have shown that inducing immunity against angiogenesis-associated products engenders potent antitumor immunity without significant pathology. It is, however, not known whether T cells corresponding to stromal products are present in humans. In this study, we describe a method to screen for human stromal products that have not triggered significant tolerance and could therefore serve as candidate antigens for cancer immunotherapy.

**Experimental Design:** To identify candidates for human stromal antigens, we used an in vitro screening method to determine whether dendritic cells transfected with mRNA encoding products, which are overexpressed in the tumor stroma, are capable of stimulating cytotoxic CD8⁺ (CTL) responses from human peripheral blood mononuclear cells.

**Results:** CTL responses could be consistently generated against fibroblast activation protein (FAP) but not against matrix metalloproteinase-9 (MMP-9) or MMP-14. To enhance the immunogenicity of the mRNA-translated FAP product, a lysosomal targeting signal derived from lysosome-associated membrane protein-1 (LAMP-1) was fused to the COOH terminus of FAP to redirect the translated product into the class II presentation pathway. Dendritic cells transfected with mRNA encoding the FAP-LAMP fusion product stimulated enhanced CD4⁺ and CD8⁺ T-cell responses.

**Conclusion:** This study identifies FAP, a protease preferentially expressed in tumor-associated fibroblasts, as a candidate human stromal antigen to target in the setting of cancer immunotherapy, and shows that differential expression of stromal products is not a sufficient criteria to indicate its immunogenicity in a vaccination setting.

The long-term therapeutic benefits of inducing potent immunity in cancer patients is threatened by the propensity of the genetically unstable tumor cells to escape immune elimination through the emergence of resistant variants (1). It is widely recognized that tumor progression beyond a minimal size is critically dependent on normal cells such as endothelial cells, smooth muscle cells, fibroblasts, and other cell types, collectively known as the tumor stroma (2). Thus, immunizing against products which are preferentially, although not necessarily exclusively, expressed by the tumor stroma could also affect tumor growth. Because stromal cells, unlike tumor cells, are diploid, genetically stable, and exhibit limited proliferative capacity, targeting the stroma could substantially reduce the incidence of immune evasion (3, 4). Stromal products also provide a source of “universal” antigens that could be targeted in every cancer patient and offer a broad spectrum of candidates from which to choose.

The notion of targeting the tumor stroma is not new. Strategies to inhibit important stromal functions required for tumor growth, such as the proteolytic activity of matrix metalloproteinases (MMP) or vascular endothelial growth factor receptor-2 signaling, are being developed and tested in clinical trials (5, 6). Yet, despite earlier predictions (3), emergence of treatment-resistant stromal cells was seen due to redundancy in the targeted functions (7). Because immune recognition of antigen-expressing targets is not affected by the expression of other products with redundant functions, immunologic targeting of the tumor stroma could be more effective at limiting the emergence of treatment-resistant variants.

Recent studies in rodent models have shown that stimulating immune responses against vascular endothelial growth factor...
their use in a vaccination setting and that functional measure—tumor milieu cannot be used as the sole or main criteria for also show that differential expression of stromal products in the setting of cancer immunotherapy. Our findings confined to tumor-associated fibroblasts, as a candidate antigen activation protein (FAP), a product whose expression is largely reduced frequency and avidity of cognate T cells. The degree of various degrees of tolerance that would be reflected in the absence of significant pathology (8, 9). We have shown that vaccination of tumor-bearing mice with dendritic cells transfected with mRNA encoding several angiogenesis-associated products, including vascular endothelial growth factor receptor-2, Tie-2, or vascular endothelial growth factor, stimulated potent antitumor immunity in murine tumor models (10).

Stromal products are “self’—antigens and may have triggered various degrees of tolerance that would be reflected in the reduced frequency and avidity of cognate T cells. The degree of tolerance induced by self-antigens is inversely proportional to their potency as antigens in a vaccination setting (11). It is currently not known whether T cells with specificity to stromal products are also present in the periphery of human individuals which can be activated to exert antigen-specific effector functions. In this study, we describe a method to screen for human stromal products that have not triggered significant tolerance and could therefore serve as candidate antigens in the setting of cancer immunotherapy. We identify fibroblast activation protein (FAP), a product whose expression is largely confined to tumor-associated fibroblasts, as a candidate antigen to target in the setting of cancer immunotherapy. Our findings also show that differential expression of stromal products in the tumor milieu cannot be used as the sole or main criteria for their use in a vaccination setting and that functional measurements such as described in this study are required.

Materials and Methods

Plasmid constructs and in vitro transcription of RNA: Cloning of matrix metalloproteinase-9, matrix metalloproteinase-14, and fibroblast activation protein plasmids. The HindIII/NdeI fragment of pGEM4Z/A64 (12) was cloned into pSP73 (Promega, Madison, WI) digested with HindIII and NdeI to generate pSP73/A64. The pSP73-Sph plasmid was created by digesting pSP73 with SphI, filling in the ends with T4 DNA polymerase and religating. pSP73-Sph/A64/Not contains a NotI restriction site adjacent to the SphI site. Human MMP-9 was amplified by PCR (primers used are shown in Table 1) from a cDNA plasmid provided kindly by Dr. Stephen Weiss (University of Michigan, Ann Arbor, MI) and was cloned into the XhoI-XbaI site of the pSP73-Sph/A64/Not plasmid. Human MMP-9 was amplified by PCR (primers used are shown in Table 1) from a cDNA plasmid provided kindly by Dr. Stephen Weiss (University of Michigan, Ann Arbor, MI) and was cloned into the XhoI-XbaI site of the pSP73-Sph/A64/Not plasmid. Human MMP-14 was amplified by PCR from the plasmid pSP73-Sph/A64/Not cut with HindIII and EcoRI by digestion with SfiI. Human FAP was amplified by reverse transcription-PCR from total human peripheral blood mononuclear cell (PBMC) RNA (primers used are shown in Table 1). The PCR product was digested with SfiI and ligated into the vector containing the gp96 signal sequence and LAMP sorting sequence. The full-length cDNA of FAP was subcloned into the SfiI-SfiI site by replacing β-actin cDNA.

In vitro transcription. Plasmids were linearized using the restriction endonuclease SpeI and in vitro transcribed using the mMESSAGEmMAXICHINE high yield capped RNA transcription kit (Ambion, Austin, TX) according to the manufacturer’s manual. After digestion of the DNA template with DNase I, RNA was purified with an RNeasy kit (Qiagen, Valencia, CA).

Dendritic cell generation from peripheral blood, RNA transfection, and maturation of dendritic cells. All cellular material used in these experiments was obtained from human subjects following informed consent through protocols approved by the Duke University Institutional Review Board. Leukapheresis-derived PBMCs were incubated for 1 hour in AIM-V medium (Life Technologies, Grand Island, NY) at 37°C to allow plastic adherence and then cultured for 6 days in AIM-V medium supplemented with 800 units/ml granulocyte macrophage colony-stimulating factor and 500 units/ml interleukin-4 (IL-4). In some experiments X-VIVO-15 medium (Cambrex Bio Science, Walkersville, MD) was used for the 6-day incubation without any significant difference. Electroporation was done as previously described (14). Immature dendritic cells were harvested on day 6, washed, and gently resuspended in Opti-MEM (Life Technologies) at 2.5 × 10⁶/ml. The supernatant from dendritic cell culture was saved as conditioned medium for later use. Cells were electroporated in 2-mm cuvettes; 200 µl of dendritic cells (5 × 10⁶ cells) at 300 V for 500 microseconds using an Electro Square Porator ECM 830 (BTX, San Diego, CA). The amount of in vitro—transcribed RNA used was 2.5 µg/10⁶ dendritic cells. Cells were immediately transferred to 60-mm tissue culture Petri dishes containing a 1:1 combination of conditioned dendritic cell growth medium and fresh medium. Cells were matured overnight with IL-1β (5 ng/ml), tumor necrosis factor-α (5 ng/ml), IL-6 (150 ng/ml), and prostaglandin E2 (1 µg/ml). IL-4, tumor necrosis factor-α, IL-1β, and

| Table 1. Primer sequences for PCR and reverse transcription-PCR |
|------------------|-----------------|
| **Amplicon**     | **Sequence**    |
| hMMP9 forward    | 5′-TATATACCTCGAGGCCACCATAGGAGCTCTGTCGCCAGC-3′ |
| hMMP9 reverse    | 5′-TATATATCTAgACTAGTCTCAGGGCAGCTCAGC-3′ |
| HMMP14 forward   | 5′-TATATATCCTAgCCACCCTGGTCTCCGGCCGGCCAAGG-3′ |
| HMMP14 reverse   | 5′-TATATATCCTAGCCAGATCTTGGCAGGGAAC-3′ |
| hFAP forward     | 5′-TATATATCCTGACCCATGAGAATTTGGGAAATTTGCCAGC-3′ |
| hFAP reverse     | 5′-TATATATCCTGACCCATGAGAATTTGGGAAATTTGCCAGC-3′ |
| hgp96 forward    | 5′-TATATATCCTGACCCATGAGAATTTGGGAAATTTGCCAGC-3′ |
| hgp96 reverse    | 5′-TATATATCCTGACCCATGAGAATTTGGGAAATTTGCCAGC-3′ |
| hLAMP1 forward   | 5′-TATATATCCTGACCCATGAGAATTTGGGAAATTTGCCAGC-3′ |
| hLAMP1 reverse   | 5′-TATATATCCTGACCCATGAGAATTTGGGAAATTTGCCAGC-3′ |
| h-Actin forward  | 5′-TATATATCCTGACCCATGAGAATTTGGGAAATTTGCCAGC-3′ |
| h-Actin reverse  | 5′-TATATATCCTGACCCATGAGAATTTGGGAAATTTGCCAGC-3′ |

www.aacrjournals.org 5567 Clin Cancer Res 2005;11(15) August 1, 2005
Downloaded from clincancerres.aacrjournals.org on July 15, 2017. © 2005 American Association for Cancer Research.
IL-6 were purchased from R&D Systems (Minneapolis, MN); granulocyte macrophage colony-stimulating factor was from Immunex (Seattle, WA) under the trade name Leukine; and prostaglandin E2 from Pharmacia (Erlangen, Germany) under the trade name Miniprostin E2.

**Induction of CD4+ and CD8+ T-cell responses in vitro.** CD8+ T cells were isolated by positive selection using EasySep CD8 Selection Kit (StemCell Technologies, Inc., Vancouver, Canada). CD8+ T cells were cocultured with antigen-transfected, matured dendritic cells (ratio 10:1) in complete T-cell medium in the presence of IL-6 (1,000 units/mL), IL-12 (10 ng/mL), and anti-IL-10 antibody (2.5 μg/mL). On day 7, the T cells were restimulated with antigen-transfected dendritic cell (ratio, 10:1) in complete T-cell medium with IL-2 (20 units/mL), IL-7 (10 ng/mL), and anti-IL-10 antibody (2.5 μg/mL). T cells were harvested on day 12 and assessed for their ability to lyse autologous immature dendritic cells transfected with specific RNA in a standard 4-hour europium release assay (15). Europium release was measured by time-resolved fluorescence (Delta fluorometer; Wallac, Gaithersburg, MD). Specific cytotoxic activity was determined with the formula: % specific release = ([experimental release – spontaneous release] / [total release – spontaneous release]) × 100.

To measure the induction of CD4+ T cell responses, T cell–enriched PBMC were used as effector cells. PBMC were negatively selected using EasySep Human T Cell Enrichment Kit (StemCell Technologies) and cocultured with antigen-transfected dendritic cells (ratio, 10:1) with IL-7 (10 ng/mL) for 7 days and restimulated for 5 days in the presence of IL-2 (20 units/mL). CD4+ T cells (5 × 10⁵) isolated by negative selection (EasySep CD8 Selection Kit, StemCell Technologies) and 5 × 10⁵ RNA-transfected dendritic cells in 100 μL of complete medium were added to each well of flat-bottomed 96-well nitrocellulose plates (Multiscreen-IP; Millipore, Bedford, MA) precoated with 1 μg/mL IFN-γ capture antibody. Plates were incubated for 20 hours at 37°C; after washing, biotinylated IFN-γ detection antibody was added to each well. Wells were then incubated for an additional 2 hours at room temperature and then streptavidin-alkaline phosphatase and substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD) was added. After washing, spots were counted using an automated Zeiss KS Elispot Compact reader (Carl Zeiss, Inc., Minneapolis, MN). Alternatively, the twice-stimulated T cells were used in a cytotoxicity assay as described above.

**Results**

The relative frequency of antigen-specific CD8+ T cells was determined by measuring the ability of autologous dendritic

---

![Fig. 1. Induction of CTL responses by dendritic cells transfected with FAP, MMP-9, MMP-14, and survivin from the PBMC of three donors. CD8+ T cells were stimulated twice with mRNA-transfected dendritic cells and used in a cytotoxicity assay as described in Materials and Methods. Cytotoxicity was determined using targets immature dendritic cells transfected with mRNA encoding the antigen used in the stimulation reaction (▲) or a control antigen (○). Control antigens used: FAP CTL, survivin, or MMP14 for donors 1 and 2 or 3, respectively; MMP-9 CTL, FAP, or MART-1 for donors 1 and 2 or 3, respectively; MMP-14 CTL, MMP-9, FAP, or MART-1 for donors 1, 2, or 3, respectively; survivin CTL and FAP for all donors.](image-url)
shown to stimulate CTL responses in vitro. Control in these studies, we measured the induction of CTL proliferating fibroblasts of healing wounds. As a positive nant adult tissue, FAP is transiently expressed in the fibroblasts of most tumors examined (18–21). In nonmalig- 

fibroblasts. It is broadly expressed in tumor-associated human malignancies by stromal cell and/or tumor cells (16). MMP-9 and MMP-14 are expressed in virtually all behavior of tumors by remodeling of the extracellular matrix (5, 16, 17). MMP-9 and MMP-14 are expressed in virtually all human malignancies by stromal cell and/or tumor cells (16). FAP is a serine protease expressed by activated proliferating fibroblasts. It is broadly expressed in tumor-associated fibroblasts of most tumors examined (18–21). In nonmalignant adult tissue, FAP is transiently expressed in the proliferating fibroblasts of healing wounds. As a positive control in these studies, we measured the induction of CTL responses against survivin, an antiapoptotic product expressed in many tumor cells and proliferating endothelial cells and shown to stimulate CTL responses in vitro from human PBMC (22–25).

Induction of CTL responses was evaluated in PBMC from six donors. T cells were stimulated with autologous dendritic cells transfected with mRNA encoding the tested antigen, and the generation of CTL was measured using standard cytotoxicity assays using mRNA-transfected dendritic cells as targets. Dendritic cells transfected with mRNA are a powerful antigen-presenting platform for stimulating human CTL responses in vitro and also provide broadly useful targets to measure antigen-specific cytotoxicity in view of the fact that autologous cells expressing the antigen in question are not readily available (26). For example, in this study, it would have been extremely laborious to generate autologous stromal cell lines expressing FAP, MMP-9, or MMP-14. In addition, dendritic cells transfected with irrelevant mRNA provide excellent specificity control in the cytotoxicity assay. Figure 1 shows the results from three donors in which all four antigens were evaluated in the same experiment. Consistent with previous reports, survivin-specific CTL responses could be generated from all four donors tested (22–25). Likewise, all three donors shown in Fig. 1 also stimulated a FAP-specific CTL response of comparable magnitude. In contrast, MMP-9- and MMP-14-specific CTL could be generated only from one of three donors shown in Fig. 1. As it is not uncommon in human in vitro CTL assays, PBMC from some donors tend to generate a high back-
ground lysis (Fig. 1: donor 3 MPP-9-CTL and MMP-14-CTL), perhaps reflecting elevated natural killer-like activity in the PBMC of this donor. A summary of all CTL assays done and numbers of donors tested is shown in Table 2. Clearly, FAP- and survivin-specific CTL could be consistently stimulated from the PBMC of human volunteers, whereas induction of MMP-9- or MMP-14-specific CTL was significantly less frequent.

Generation of robust and durable CD8\(^+\) CTL responses also requires the concomitant induction of CD4\(^+\) T helper responses (27). Vaccination with nucleic acid encoded antigens, such as mRNA-transfected dendritic cells used in this study, favors the generation of class I–restricted CD8\(^+\) T cell responses because the translated antigen will be channeled preferentially into the endogenous class I presentation pathway. To provide CD4\(^+\) T help, a lysosomal targeting signal derived from the LAMP-1 was fused to the carboxyl end of FAP to enhance access of the antigen to the class II presentation pathway (28). We have previously shown that dendritic cells transfected with mRNA- 

encoded LAMP-1 modified carcinoembryonic antigen or TERT antigens stimulated in vitro enhanced CD4\(^+\) T-cell responses as well as enhanced CD8\(^+\) CTL responses that were especially evident when IL-2 was omitted from the incubation reaction (13, 15). The potential value of vaccination with LAMP-modified antigens was underscored in a recent clinical trial whereby vaccination of patients with LAMP-modified but not with unmodified TERT antigen was capable of stimulating TERT-specific CD4\(^+\) T-cell responses (29).

T cells were stimulated with FAP or FAP-LAMP mRNA-transfected dendritic cells and the induction of FAP-specific CD4\(^+\) T-cell and CD8\(^+\) CTL responses were determined as described in Materials and Methods. As shown in Fig. 2, fusion of the LAMP-1-derived sequences to the COOH end of FAP enhanced the generation of FAP-specific IFN\(\gamma\)-secreting CD4\(^+\) T cells. Figure 3 shows that LAMP-modified FAP mRNA-transfected dendritic cells stimulated a more potent CTL response, especially evident when IL-2 was omitted from the culture. These observations are consistent with our previous observations (13, 15) and show that the endogenously expressed mRNA-translated LAMP-1 modified FAP product is

| Table 2. Human \textit{in vitro} CTL assays |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Donor | Donor | Donor | Donor | Donor | Donor | Sum |
| 1 | 2 | 3 | 4 | 5 | 6 |
| FAP | 12/12 | 3/3 | 3/4 | 1/1 | 2/2 | 2/2 | 23/24 |
| MMP-9 | 2/2 | 0/3 | 0/2 | 0/2 | 0/2 | 2/9 |
| MMP-14 | 2/2 | 2/4 | 1/2 | 0/1 | 0/3 | 5/13 |
| Survivin | 6/6 | 1/1 | 2/2 | 1/1 | — | 10/10 |

NOTE: The numbers given reflect positive CTL results per total number of CTL assays done. CTL results are considered positive when (i) lysis of specific targets is higher than control targets in at least four of five E/T ratios and (ii) the difference between the lysis of specific and control targets is at least 2-fold and not <10%.

Fig. 2. Stimulation of FAP-specific CD4\(^+\) T cell responses by chimeric FAP-LAMP mRNA-transfected dendritic cells. T cells were stimulated twice with mRNA-transfected dendritic cells as described in Materials and Methods. CD4\(^+\) T-cells isolated by negative selection were incubated with mRNA-transfected dendritic cells as indicated, and the numbers of IFN\(\gamma\)-secreting cells was determined by ELISPOT.
activated to exert effector functions. We have shown that
relative abundance of antigen-specific T-cell precursors that can
responses
Fig. 3. Stimulation of FAP-specific CD8+ T-cell responses by chimeric FAP-LAMP
mRNA-transfected dendritic cells. T cells were stimulated twice with
mRNA-transfected dendritic cells as described in Materials and Methods.
Restimulated T cells were incubated in the presence (top) or absence (bottom)
of IL-2 and used in a cytotoxicity assay. Target cells were immature dendritic cells
transfected with FAP mRNA (▲) or MMP-14 mRNA as control antigen (○).
retargeted into the class II presentation pathway leading to
enhanced induction of CD4+ T-cell responses which in the
absence of an exogenous source of IL-2 provided “help” for the
generation of CTL responses.

Discussion
In this study, we described a screening strategy to assess the
relative suitability of tumor stromal products to serve as
antigens in the setting of cancer vaccination. By measuring
the ability of stromal products to stimulate CD8+ CTL responses in vitro
from donor PBMC, we could determine the relative abundance of antigen-specific T-cell precursors that can
be activated to exert effector functions. We have shown that
FAP, but not MMP-9 or MMP-14, precursors are present at high
frequency in the PBMC (Fig. 1). Conceivably, despite the fact
that self products such as MMP-9 or MMP-14 are overexpressed
in the tumor environment, they have triggered a significant
degree of tolerance as judged by the fact that compared with
survivin or FAP it was more difficult to stimulate CTL responses
against these antigens. These findings, therefore, suggest that
FAP, a product whose expression is largely confined to tumor-
associated fibroblasts, would be a more effective antigen to
target in the setting of cancer immunotherapy. These observations
also show that differential expression of antigenic candidates is not sufficient to guide their choice for use in a
vaccination setting and that functional measurements such as
described in this study are necessary. In addition, our study has
shown that LAMP-modified FAP mRNA-transfected dendritic
cells exhibit enhanced capacity to stimulate CD4+ and CD8+
T-cell responses in vitro. In light of the fact that LAMP-modified
antigens were also capable of stimulating enhanced CD4+ T-cell
response in human patients (29), LAMP-modified FAP would
be a reasonable choice for further evaluation in murine tumor
models and in a human clinical trials.

The screening method used in this study is semiquantitative
and comparative in its nature; its primary value is to eliminate
less suitable candidates, in this instance, MMP-9 or MMP-14.
The use of mRNA as antigenic template and mRNA-transfected
autologous dendritic cells as targets in the T-cell assay extends
the applicability of this analysis to virtually every antigen.
Nevertheless, in vitro human T-cell assays cannot evaluate the
biological effect of vaccination against FAP or other (self)
antigens on tumor growth and/or induction of autoimmune
pathology. These variables can be assessed in rodent tumor
models provided suitable homologous antigens exist. Indeed,
preliminary observation from murine studies suggest that
FAP, and in particular FAP-LAMP, vaccination is capable of
stimulating potent antitumor immunity in the absence of
significant toxicity.1 The not surprising variability among
normal products in stimulating T-cell responses from human
PBMC as shown in Fig. 1 suggests that screening of human
antigenic candidates should precede murine studies assessing
their biological effect (i.e., tumor growth and autoimmunity).

References
1. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S.
Escape of human solid tumors from T-cell recognition:
2. Liotta LA, Kohn EC. The microenvironment of the
1135–49.
6. Cherrington JM, Strawn LM, Shawver LK. New para-
digms for the treatment of cancer: the role of anti-
acquired resistance to anti-angiogenic drugs: implica-
tions for the use of combination therapy approaches.
Cancer Metastasis Rev 2001;20:79–86.
against the vascular endothelial growth factor receptor
flk1 inhibits tumor angiogenesis and metastasis. J Exp
vaccine against VEGF receptor 2 prevents effective
angiogenesis and inhibits tumor growth. Nat Med
2002;8:1369–75.
10. Nair S, Boczkowski D, Moeller B, Dewhirst M,
Vieweg J, Gilboa E. Synergy between tumor immuno-
therapy and antiangiogenic therapy. Blood 2003;
12. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa
E. Induction of tumor immunity and cytotoxic T lym-
phocyte responses using dendritic cells transfected
with messenger RNA amplified from tumor cells.
of tolomeosome–specific CD4+ T cells using dendritic
immature dendritic cells into adjutant-treated skin
oblivates the need for ex vivo maturation. J Immunol
2003;171:6276–82.
15. Nair SK, Boczkowski D, Morse M, Cumming RI,
Lyerly HK, Gilboa E. Induction of primary carcinoem-
byronic antigen (CEA)-specific cytotoxic T lym-
phocytes in vitro using human dendritic cells transfected
16. Egeland M, Werb Z. New functions for the matrix
metalloproteinases in cancer progression. Nat Rev
17. Coussens LM, Fingleton B, Matrisian LM. Matrix

1 Unpublished data.


Induction of CD4+ and CD8+ T-Cell Responses to the Human Stromal Antigen, Fibroblast Activation Protein: Implication for Cancer Immunotherapy

Martin Fassnacht, Jaewoo Lee, Caterina Milazzo, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/11/15/5566

Cited articles
This article cites 28 articles, 15 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/11/15/5566.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/11/15/5566.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.